Method for treatment of suppurative wound

FIELD: veterinary science, surgery.

SUBSTANCE: method involves applying the application of mixture comprising glue base with ligfol and Novocain on infected surface taken in the ratio, wt.-%: ligfol, 70; Novocain, 30. Method allows decreasing time for treatment of suppurative wounds by 1.5-2 times, economy of dressing material and time that improved labor conditions of veterinary expert. Invention can be used in treatment of suppurative wounds both aerobic and anaerobic etiology.

EFFECT: improved treatment method.

1 ex

 

The invention relates to veterinary medicine, namely to surgery, and can be used for the treatment of wounds both aerobic and anaerobic etiology.

There is a method of treatment of purulent wounds by applying on the surface of infected applications of polymeric compositions containing antiseptic - brilliant green, and the adhesive base (description A.S. 288866 SU a 61 L 15/06).

Brilliant green has a weak antiseptic wound healing property, which increases the duration of treatment of purulent wounds.

The technical result of the invention is the reduction of treatment time random by RAS activation as rehabilitation and regenerative process of injured tissues.

The technical result is achieved in that in the method of treating wounds comprising applying to the surface of infected mix adhesive with wound-healing agent in the form of appliques, as healing tools use ligfola and novocaine, and as adhesive - adhesive base containing water, and polyvinyl alcohol, in the following ratio of the components of wound healing products, wt.%:

the ligfola70
novocaine30

The ligfola is a complex drug, which includes guminova the acid, obtained by hydrolysis of natural (wood) lignin, sodium pyrophosphate desativada, sodium chloride and demineralizovannaja water. He is an effective adaptogen and cress proofreader with a complex mechanism and a broad spectrum of action. The ligfola as a macromolecule, Faeroese by leukocytes and undergoes hydrolysis and, thus, is activated, leading to phenol. As shown by experimental and clinical studies, ligfola increases or maintains the level of humoral defense factors in inflammation. The most pronounced effect of the drug on cellular immunity as in the whole organism, and, remarkably, directly into the inflammatory focus. Use ligfola in the treatment process provides immuno-antioxidant mechanisms in the wound, and in combination with novocaine, which in the animal body is hydrolyzed, forming para-aminobenzoic acid, and allows to significantly reduce the alteration and exudation in it. As a result of accelerated process of cleansing the wound from tissue debris and pathogenic microflora and stimulates reparative processes.

Adhesive base containing water, and polyvinyl alcohol, ensures the formation on the surface of the wound film with high gas permeability.

Carry out a method of treatment of purulent is Ana, daily deals on the surface of infected wounds animal applique composite mixture comprising the adhesive base, ligfola and novocaine. Quantitative composition of ingredients in the composition of the mixture is adjusted individually (depending on the area of the wound and the nature of purulent-inflammatory processes). While the quantitative composition of wound healing agents can be chosen according to the recommendations of Counsel to the agents ligfola and novocaine. Quantitative selection of the adhesive is determined by its mechanical properties and conditions of strong anchoring on the wound.

The application is fixed on the wound surface. In the wound cavity created anaerobic conditions impeding the development of aerobic microflora. Anaerobic infection does not develop, as the end product of hydrolysis ligfola is a substance in action similar to phenol. The treatment in a period of 14-15 days until complete wound healing with high quality epithelialization of the wound surface.

Example.

For the treatment of incised wounds in dogs infected with Staphylococcus aureus, with clear signs of inflammatory process to prepare the mixture for the application used adhesive base containing water, and polyvinyl alcohol. Part of wound healing products, included ligfola and novocaine at the ratio, wt.%: the ligfola - 70, mode is in 30.

On the day 3 animals showed a significant reduction of active hyperemia of the skin and inflammatory edema around the wound. Seats were visible Islands of granulation tissue. On the 5th day the animal was active cleansing wounds from purulent-necrotic masses, the wound surface area decreased by 26.8%. 8 days was the full implementation of the wound surface quality granulation tissue. By this time, due to the contraction and epithelialization square RAS decreased significantly and averaged 121±1.4 mm2i.e. decreased by 69.8% compared to the original. For 12 hours the area of wounds in dogs decreased by 94.2 percent. Complete healing with quality epithelialization of the wound surface occurred on average by 14.5 day.

The proposed method is compared with the prototype allows to shorten the time of treatment of purulent wounds in 1,5-2 times, save dressings and accordingly the time, which improves working conditions veterinary specialist.

A method of treating wounds comprising applying to the surface of infected mix adhesive with wound-healing agent in the form of applications, characterized in that as healing tools use ligfola and novocaine, and as adhesive - adhesive base containing water, and polyvinyl alcohol,in the following ratio of the components of wound healing products, wt.%:

The ligfola70
Novocaine30



 

Same patents:

FIELD: medicine.

SUBSTANCE: the present innovation deals with ways for purifying blood plasma in burnt patients followed by applying the plasma obtained either while carrying out the next plasmapheresis or as independent transfusion medium. For this purpose, it is necessary to carry out plasmapheresis in burnt patients. Heparin should be added into plasma removed during plasmapheresis and, additionally, hemodesis, followed by incubation at +4° C for about 5-18 h, then it should be centrifuged for depositing cryoprecipitate. The innovation suggested enables to alter conditions of cryoprecipitation so, that it is possible to increase precipitation of fibrinogen and fibrin-monomeric complexes, the quantity of which is sharply observed in burnt patients.

EFFECT: higher efficiency of purification.

1 tbl

FIELD: medicine.

SUBSTANCE: method involves making surgical intervention after Widman with patient blood taken in the amount of 10-20 ml before placing flap. The blood is centrifuged during 11-13 min at 2400-2800 rpm and divided into 3 fractions like erythrocytes, plasma of high blood platelets content and plasma of low blood platelets content as a result of the treatment. The plasma of high blood platelets content is taken from laboratory glass and mixed with beta-tribasic calcium phosphate powder in proportion of 1:3. Then, the produced mixture is placed into defect zone and the flaps are fixed with sutures.

EFFECT: no additional surgical intervention needed; excluded allergic responses.

FIELD: medicine, surgery.

SUBSTANCE: method involves using dimexide 100% solution in 2% Novocain taken in the ratio 1:1 that is used as a compress for 30 min. Invention promotes to enhancing the effectiveness of preoperational treatment in simultaneous effect on pain endings. Invention can be used in carrying out preoperational treatment of skin.

EFFECT: improved treatment method.

1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with preventing hemodynamic complications at restoring circulation in a prolongly ischemized limb, or due to premeditated tourniquet application during operative interference. For this purpose, 5-12 min before the onset of circulatory restoration it is necessary to start intravenous injection of antihistamine and glucocorticosteroid preparations, followed by drop-by-drop infusion of inhibitors of proteolytic enzymes which should be continued after tourniquet removal, as well. The method provides tourniquet shock and tourniquet shock-associated complications along with developing the chance for increasing the duration period of operation.

EFFECT: higher efficiency of prophylaxis.

3 ex

FIELD: medicine, proctology.

SUBSTANCE: the present innovation deals with introducing a sclerosing preparation consisting of equal parts of 96% alcohol and 2% lidocain at the quantity of 2-4 ml, for all fissures it is necessary to inject 10 ml 0.5%-novocain solution and 2 ml solcoseryl or actovegin, then one should change the direction to move a needle towards coccyx towards sphincter's external diameter to introduce 5 ml 0.5%-Novocain solution and, not shifting a needle, one should introduce a sclerosing preparation. The innovation enables to conduct simultaneously the following procedures: anesthesia, the rupture of adhesions, blocking painful and sensitive branches of pudendal nerve that innervate ulcerous area that leads then to decreased pain syndrome, decreased sphincter's spasm and better ulcer's healing.

EFFECT: higher efficiency of sclerotherapy.

2 dwg, 2 ex

FIELD: medicine, surgery.

SUBSTANCE: the present innovation deals with treating patients in early post-operational period after interferences in mediastinal and esophageal organs. One should conduct the course of subxyphoidal bolus injection of lymph-stimulating mixture containing 64 U lidase diluted in 1 ml 5%-glucose, 25 mg suspension of hydrocortisone followed by slow drop-by-drop injection of 500 mg metrogil during the first 3 d of post-operational period. The innovation provides high concentration of curative preparations in operation region at decreasing their dosages, decreased toxic effects and risk of purulent-inflammatory complications due to stimulating drainage-detoxication function of lymph system.

EFFECT: higher efficiency.

1 ex

FIELD: medicine.

SUBSTANCE: the present innovation should be fulfilled due to performing sclerotherapy with 96%-ethanol under ultrasound control at the dosage of 0.5-1 ml/ml of nodal volume in case of nodal neoplasms and 3-5 ml in case of cystic neoplasm after liquid aspiration. Moreover, a day before each course of sclerotherapy one should introduce Movalis for 5-10 d once daily after meals. The course of sclerotherapy should be started with introducing 96%-ethanol, then 8-10 d later it is necessary to introduce benzyl peniccilin sodium salt at the dosage of 0.5-1 ml/ml of nodal volume in case of nodal neoplasm, and 0.5 ml after liquid aspiration - in case of cystic neoplasm. The innovation enables to decrease side manifestations of complex therapy performed due to decreasing the quantity of injections.

EFFECT: higher efficiency of therapy.

1 cl, 4 ex

FIELD: medicine, surgery.

SUBSTANCE: one should apply a hemostatic film onto damaged spleen, moreover, as hemostatic material one should apply hyaluronic acid-based film (HA) being chemically associated with 5-aminosalicylic acid and impregnated with ferrum of the following total structural formula:

. Moreover, substitution degree of carboxylic groups with 5-aminosalicylic acid corresponds to 30-50% M. The innovation provides stimulation of fibroblastic activity and accelerated formation of granulations.

EFFECT: higher efficiency of therapy.

8 dwg

FIELD: medicine, surgery.

SUBSTANCE: method involves using chlorhexidine aqueous solution saturated with carbon dioxide by bubbling that is fed into wound with simultaneous evacuation its from wound with wound secret. Sanitation is carried out by two séances per 24 h for 10-20 min. Invention promotes to mechanical cleaning wound surface, effective bacterial decontamination, improving proliferative processes that, in turn, promotes to rapid wound healing. Invention can be used for treatment of suppurative-inflammatory processes in closed cavities and wound infections.

EFFECT: improved treatment method.

3 cl

FIELD: medicine, surgery.

SUBSTANCE: on should perform continuous washing patient's foot for several days due to placing it into hermetically sealed reservoir with antiseptic followed by vacuum evaporation at rarefaction being 0.2-0.4 kgf/sq. cm, moreover, procedures should be alternated at periodicity of 3-4 h. The present innovation enables to accelerate wound purification and increase regenerative activity of plantar tissues due to suppressing activity of the agent of purulent-necrotic process, activation of local immunity of affected tissues and restoration of microcirculation and oxygenation of these tissues.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: veterinary science.

SUBSTANCE: invention involves the combined use of antibacterial preparations and immunomodulator. Method involves complex of single and double RNA sodium salts from killer yeast Saccharomyces cerevisiae as an immunomodulator and synthetic polymer-carrier taken in the dose 0.3-0.4 mg/kg. Immunomodulator is administrated in animals in a single dose before onset of critical period, i. e. in 15-20 days of piglets growing. Method provides stimulation of factors of cellular and humoral immunity of animals without adverse reactions and complication due to selection of optimal dose of immunomodulator and its prolonged effect.

EFFECT: improved method for treatment and prophylaxis.

3 cl, 4 tbl, 3 ex

FIELD: medicine, virology, chemical-pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to a synergetic composition comprising azidothymidine and glycyrrhizic acid penta-O-nicotinate - niglizine taken in physiologically blood concentrations: 0.0037-0.0254 mcM for azidothymidine and 0.0052-9.64 mcM for niglizine. Using the proposed composition provides effective inhibition of HIV-1 reproduction and significant reducing consumptions required for treatment. The composition shows high bioavailability and high effectiveness.

EFFECT: improved and valuable medicinal properties of composition.

6 tbl, 1 dwg

FIELD: veterinary science.

SUBSTANCE: invention proposes a preparation for treatment and prophylaxis of mastitis in cows at onset of the lactation period and in dry cows that comprises the following components, wt.-%: furacrylin, 0.4-0.6; dioxydin, 0.8-1.2; bee wax, 4-6, and sunflower oil, the balance. The preparation is heated to 38-40°C and administrated in cow mammary gland being in damaged and healthy lobules of udder through a nipple duct by using a syringe in the dose 5 ml. Using the preparation provides enhancing therapeutic and prophylactic effectiveness, decreasing labor intensity in treatment and prophylaxis of mastitis in cows at the lactation period and in dry cows.

EFFECT: enhanced and valuable properties of preparation.

3 tbl, 3 ex

FIELD: veterinary science.

SUBSTANCE: invention proposes a preparation for treatment and prophylaxis of mastitis in cows at onset of the lactation period and in dry cows that comprises the following components, wt.-%: furacrylin, 0.4-0.6; dioxydin, 0.8-1.2; bee wax, 4-6, and sunflower oil, the balance. The preparation is heated to 38-40°C and administrated in cow mammary gland being in damaged and healthy lobules of udder through a nipple duct by using a syringe in the dose 5 ml. Using the preparation provides enhancing therapeutic and prophylactic effectiveness, decreasing labor intensity in treatment and prophylaxis of mastitis in cows at the lactation period and in dry cows.

EFFECT: enhanced and valuable properties of preparation.

3 tbl, 3 ex

FIELD: pharmacy.

SUBSTANCE: invention relates to metronidazol-base antiprotozoan preparation possessing broad spectrum of action with respect to protozoa. Proposed agent is made as tablets based on metronidazol and comprises polyvinylpyrrolidone, filling agent and powdering agent also. Microcrystalline cellulose is used as a filling agent, and a mixture of cross-linked homopolymer of N-vinyl-2-pyrrolidone with the nitrogen content 11-12.8% and poly-(2-oxypyrrolidine-1-ylethylene) with K- viscosity value 22.5-26.7 and taken in the ratio = (1-5):1, respectively, is used as polyvinylpyrrolidone. Invention provides enhancing strength of tablet in combination with its rapid degradation in water.

EFFECT: improved pharmaceutical properties of agent.

1 tbl

FIELD: medicine, organic chemistry, pharmacy.

SUBSTANCE: invention relates to an antibacterial preparation based on α-aminosulfonic acid amide, i. e. N'-methyl-1-phenyl-1-N,N-diethylaminomethanesulfonamide that can be used in veterinary science. Invention relates to expanding assortment of agents used against pathogenic pathogen with a preparation relating to class of α-aminosulfonic acid amides eliciting antibacterial activity being without cumulative properties and pathological changes in animal organs and tissues.

EFFECT: valuable veterinary properties of preparation.

1 tbl, 1 ex

FIELD: organic chemistry, chemical technology.

SUBSTANCE: invention relates to synthesis of new polyelectrolytes of cationic type based on diallylamine trifluoroacetate representing monomers of order both N,N-diallylamine and N,N-diallyl-N-methylamine. Invention describes polydiallylamines of the general formula: wherein R means hydrogen atom (H), -CH3; n = 107-308 (weighted mean degree of polymerization); molecular mass = 24000-65000 g/mole (weighted mean molecular mass); width of molecular-mass distribution δ = 1.85. Their aqueous solution can be used as a disinfecting agent in the minimal inhibitory concentration from 1.25 x 10-4 g/ml to 1.5 x 10-6 g/ml. Invention can be used in different branches of industry, in particular, in medicine.

EFFECT: valuable properties of compounds.

2 cl, 5 tbl, 4 dwg, 2 sch

FIELD: medicine.

SUBSTANCE: method involves incubating antibiotics and/or chemopreparations in therapeutic doses with autoplasma 30 min at 37°C and introducing the preparations into paravaginal cellular tissue to patients suffering from genitalia diseases and into paravesical cellular tissue to patients suffering from urinary bladder diseases and into pararectal cellular tissue to patients suffering from rectum diseases. Tumor proliferation into neighboring small pelvis organs (into paravaginal and/or pararectal and/or paravesical cellular tissue) taking place, the treatment is applied twice a week.

EFFECT: increased pathological focus regression percent; reduced manifestations of drug therapy complications.

FIELD: medicine, immunology.

SUBSTANCE: vaccine Rudivax is administered to group of girls not younger than 13 years old leaving Thule regions not later than 55 days before departure. Similarly group of homing girls not younger than 13 years old are vaccinated not early than 90 days after coming in Thule regions from other climatic regions.

EFFECT: presence of protective titers of anti-rubella antibodies in vaccinated girls for 1 year after vaccination.

6 ex

FIELD: veterinary virology and biotechnology.

SUBSTANCE: claimed vaccine contains antigen material from infective cattle rinotracheitis virus strain, reproduced in specific passage cell cultures having biological activity of at least 6.0 lg TCD50/cm3 and inactivated with aminoethyl ethyleneimine, and oily adjuvant in mass ratio of 30.0:70.0, respectively. Aforementioned virus strain is reproduced in specific passage cell cultures and has cytopathic action and during incubation for 48-96 h in accumulated in titer of 6.5-8.0 lg TCD50/cm3. Aminoethyl ethyleneimine is used in concentration of 0.1-0.2 % followed by neutralization thereof with sodium thiosulfate.

EFFECT: vaccine with high antigenic and immunogenic activity and safety; enhanced assortment of specific agents for infective cattle rinotracheitis prophylaxis.

15 cl, 6 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: method involves setting two thoracoports into pleural cavity after determining fistula position using bronchoscope. Conducting thread is introduced through fibrobronchoscope canal. Draining tube is introduced through manipulation thoracoport and connected to suction unit. Fistula canal is catheterized along the conducting thread to a depth of 1.0 cm and glue suspension is supplied through it.

EFFECT: enhanced effectiveness of treatment; longer extent of fistula glue treatment.

5 dwg

Up!